Bladder Cancer: Upstaging and Risk Mitigation with Blue Light Cystoscopy in NMIBC Featured at ASCO GU 2025
The poster presentation (Abstract No. 686, Poster Session B: Urothelial Carcinoma) “Upstaging and risk mitigation with Blue Light Cystoscopy for non-muscle-invasive bladder cancer: Results from a prospective multicenter registry” by Alireza Ghoreifi (Duke University Medical Center).
The study looked at 2,854 NMIBC* patients from the US Blue Light Cystoscopy with Cysview Registry. A total of 201 (7%) patients had at least one malignant lesion detected exclusively by BLC while having a negative WLC. These lesions (335 in total) included carcinoma in-situ (CIS) (145; 43%), low-grade Ta in (53; 16%), high-grade Ta in (95; 28%), high-grade T1 (37; 11%), and high-grade T2 (5; 1%). As a result of BLC-enhanced detection, the rate of upgrading or upstaging to a more advanced tumor using BLC was 9.3%. The author concluded that resulting changes in grade/stage could impact patient management, such as the appropriate administration of intravesical therapy, duration of therapy, and when to perform radical cystectomy. The results are expected to form the basis for further studies on how Blue Light Cystoscopy can support precision diagnostics and improve patient management in NMIBC.
The abstract presentation included data from Photocure’s US Blue Light Cystoscopy with Cysview Registry, a large multicenter bladder cancer patient registry of real-world data, established by Photocure in 2014 and projected to enroll 4,400 patients.
Source: Photocure ASA. (2025). Bladder Cancer: Upstaging and Risk Mitigation with Blue Light Cystoscopy in NMIBC Featured at ASCO GU 2025 [Press release]. https://photocure.com/newsletters/news-from-photocure-4990167?utm_source=email&utm_medium=email_campaign&utm_campaign=newsletter.
Related Content:
ASCO GU 2025: Upstaging and Risk Migration With Blue Light Cystoscopy for Non–Muscle-Invasive Bladder Cancer: Results From a Prospective Multi-Center Registry